mTOR signaling pathway and mTOR inhibitors in cancer therapy.
about
The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumorsThe preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agentNVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro.Autophagy plays a critical role in ChLym-1-induced cytotoxicity of non-hodgkin's lymphoma cellsNovel molecular targets for urothelial carcinomaRadio-sensitization effect of an mTOR inhibitor, temsirolimus, on lung adenocarcinoma A549 cells under normoxic and hypoxic conditions.Preclinical Evaluation of Liposomal C8 Ceramide as a Potent anti-Hepatocellular Carcinoma Agent.Recognition and Management of Oral Mucosal Injury Caused by Mammalian Target of Rapamycin Inhibitors: A Case SeriesConcurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth in vitro and in vivoTudor-SN Regulates Milk Synthesis and Proliferation of Bovine Mammary Epithelial CellsHuman metastatic melanoma cell lines express high levels of growth hormone receptor and respond to GH treatment.Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells.Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors.Molecular targets on the horizon for kidney and urothelial cancer.Rapamycin-resistant effector T-cell therapy.Signaling pathways and mechanisms of hypoxia-induced autophagy in the animal cells.Expression of TGF-β1/mTOR signaling pathway in pathological scar fibroblasts.Ketogenic Diet and Cancer-a Perspective.Safety profile and treatment response of everolimus in different solid tumors: an observational study.Everolimus as second-line therapy for metastatic renal cell carcinoma: a 'real-life' study.Upregulation of the expression of prodeath serine/threonine protein kinase for programmed cell death by steroid hormone 20-hydroxyecdysone.Preclinical study of CC223 as a potential anti-ovarian cancer agent.Metformin induces degradation of mTOR protein in breast cancer cells.Inhibition of mammalian target of rapamycin by rapamycin increases the radiosensitivity of esophageal carcinoma Eca109 cells.Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer.Developing a novel dual PI3K-mTOR inhibitor from the prodrug of a metabolite.ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activity in vitro and in vivo.Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis.mTOR Cross-Talk in Cancer and Potential for Combination Therapy.Hypoxia Pathway Proteins As Central Mediators of Metabolism in the Tumor Cells and Their Microenvironment.Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.Sunitinib resistance in renal cell carcinoma.Dual targeting of mTORC1 and mTORC2 by INK-128 potently inhibits human prostate cancer cell growth in vitro and in vivo.eIF4E Phosphorylation in Prostate Cancer.
P2860
Q26740374-C0BEA278-64D8-4D9A-8E9E-70DDC786989DQ33728258-6288C116-9020-4FED-9927-2BDCA894BF6AQ34679652-D27E9E91-3C53-4489-9259-0077DD590338Q34981512-F159CC08-9311-4DB3-AEE2-79A8DAF57997Q35527068-84473D3D-3780-47AA-919A-1D437C52F412Q35835131-8483BEF8-72A0-4CD3-910C-9775A8EC7D17Q35884228-57BFCE75-1349-4078-A1D6-08AA5E41CAE9Q36118205-D02F3AA5-4FAC-4F55-9A4B-1AA91B41D8BAQ36296641-757C9D87-1ABD-41B5-A0BA-3FA431A7CCF1Q36404318-FE3121C7-14E3-40FA-A542-E6CBCBFB4561Q37374857-5911DBFE-5B8A-4DBD-B178-C5548F8CB918Q37705988-ECA645CA-672F-4E69-A336-CAFFED562D1EQ38074121-EAE0DF31-831F-49A3-AD2F-39E6BB7A6E48Q38132039-0A7A15BE-57C0-4096-8972-4B6CB8DAEA65Q38170502-6DDDEA8A-EE6A-4B62-B586-648DA7DB4182Q38391004-398A24FC-747C-4AAD-B91D-06E0A36C8A88Q38845128-B1AF0CC5-1890-4E82-8B67-AFA5AEB5B8B2Q38936285-D85ED9E7-3618-44CA-B4BB-778277215497Q39141798-69D02C97-9A22-4A3A-A77C-CC16C0691B3AQ39150764-D1F0E59A-0BE9-4E18-9C80-4B1B42A90CFBQ39234144-876A9B48-B609-4683-B19C-2D3273A6FB1DQ41709197-18738B55-A184-4CB1-938E-512A026150DDQ42364561-C5680D9B-70E6-408F-8DC8-14A9A0BB3A31Q42720320-DDDA795F-5BD9-46B7-92CD-67AF554BD6E9Q44294451-BB496424-C14B-4901-95A9-4D1A2A28C9A5Q44318431-D2A92ABA-1AAA-49C5-829A-5B6B9230D7DDQ47103348-47B7F145-6F66-421A-A32B-8881B177BE19Q48252794-B8D82DE3-8888-4A2A-935D-88B43796BA1AQ48530866-4C16447D-527E-47E9-B120-FE3C750ABAB6Q49725890-9B9E70DF-8013-44D9-9DE5-AE3C3226856EQ51272851-B5192472-ED0E-463E-B640-A70291F3066AQ51763292-39C382E0-3F78-4E4C-9DB5-7BF60482BA70Q52942169-5A86B117-597B-46D9-9D40-FB3A3C7A4F5FQ53687330-01B7E48B-2F3F-4FFA-996D-FE1E6B34C310
P2860
mTOR signaling pathway and mTOR inhibitors in cancer therapy.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
mTOR signaling pathway and mTOR inhibitors in cancer therapy.
@en
type
label
mTOR signaling pathway and mTOR inhibitors in cancer therapy.
@en
prefLabel
mTOR signaling pathway and mTOR inhibitors in cancer therapy.
@en
P1476
mTOR signaling pathway and mTOR inhibitors in cancer therapy.
@en
P2093
Alejandro Gomez-Pinillos
Anna C Ferrari
P304
483-505, vii
P356
10.1016/J.HOC.2012.02.014
P577
2012-03-31T00:00:00Z